CD38 and plasma cell myeloma: CD38 monoclonal antibody daratumumab is a fully human IgG1 monoclonal antibody specifically targeting the CD38 molecule expressed on the surface of myeloma cells, exerting anti-myeloma activity through immune-mediated mechanisms, the direct induction of cell apoptosis, and immunomodulation [86].